1. Home
  2. AROW vs TRDA Comparison

AROW vs TRDA Comparison

Compare AROW & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arrow Financial Corporation

AROW

Arrow Financial Corporation

HOLD

Current Price

$37.37

Market Cap

600.9M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$13.73

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AROW
TRDA
Founded
1851
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
600.9M
481.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
AROW
TRDA
Price
$37.37
$13.73
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$28.00
$21.00
AVG Volume (30 Days)
93.4K
146.3K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
3.23%
N/A
EPS Growth
49.72
N/A
EPS
2.65
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
$33.36
$39.97
Revenue Next Year
$18.26
$50.80
P/E Ratio
$14.03
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.36
$4.93
52 Week High
$38.09
$14.49

Technical Indicators

Market Signals
Indicator
AROW
TRDA
Relative Strength Index (RSI) 77.65 55.94
Support Level $31.14 $10.84
Resistance Level N/A $13.99
Average True Range (ATR) 0.82 0.70
MACD 0.26 0.00
Stochastic Oscillator 85.08 67.23

Price Performance

Historical Comparison
AROW
TRDA

About AROW Arrow Financial Corporation

Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services, including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of the company's revenue is interest income, fees, commission earned through its subsidiaries.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: